ClinicalTrials.gg
Active, not recruitingNCT00716066Updated Feb 27, 2026

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

A Phase 2 interventional study of Anti-Thymocyte Globulin and Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Disease, Neurologic Autoimmune Disease and Autologous Transplant Autoimmune, sponsored by Fred Hutchinson Cancer Center. Active, not recruiting at 3 sites in United States. Open to participants aged Up to 71 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionAutoimmune Diseases of the Nervous SystemRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autoimmune Diseases of the Nervous System
Why
  1. The study's listed conditions name Autoimmune Diseases of the Nervous System, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
Up to 71 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States — 7 open to participants now, 10 under way, 2 of them phase 3. Autoimmune Diseases of the Nervous System · United States.

Enrollment
11th of 21
53 · median 53
Started
2008
the only one that year
Phase 2
9 of 28
2 open now
Registered
2nd of 28
by date

Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2008, is one of 9 in phase 2, and was the 2nd registered.

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

Browse Autoimmune Diseases of the Nervous System studies →

Open to participants now

7 of the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: Up to 71 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.

Read the detailed description

OUTLINE:

Patients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days 7-21, followed by 2 week taper.

After completion of study treatment, patients are followed up at 3 months, 1 year, and then annually thereafter for up to 5 years.

03

Conditions studied

  • Autoimmune Disease
  • Neurologic Autoimmune Disease
  • Autologous Transplant Autoimmune
  • Multiple Sclerosis Transplant
  • MS Stem Cell Transplant
  • Multiple Sclerosis Stem Cell Transplant
  • Stiff Person Syndrome
  • HCT for Neurologic Autoimmune Disorders
  • CIDP Transplant
  • Myasthenia Gravis Transplant
  • Autoimmune Nervous System Disorder
  • Central Nervous System Vasculitis
  • Cerebellar Degeneration
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Lambert Eaton Myasthenic Syndrome
  • Myasthenia Gravis
  • Neuromyelitis Optica
  • Opsoclonus Myoclonus Syndrome
  • Rasmussen Subacute Encephalitis

Keywords

  • neurologic autoimmune disease
  • autologous transplant autoimmune
  • multiple sclerosis transplant
  • MS stem cell transplant
  • multiple sclerosis stem cell transplant
  • Stiff Person Syndrome
  • HCT for neurologic autoimmune disorders
  • CIDP transplant
  • myasthenia gravis transplant
04

In context

Autoimmune Diseases of the Nervous System Reclassified

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's enrollment of 53 is above the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.

Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.

Compared within Autoimmune Diseases of the Nervous System, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an disorder of the central or peripheral nervous system will be eligible; this will include:

    • Primary Central Nervous System (CNS) vasculitis
    • Rasmussen's encephalitis
    • Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG, anti-ganglioside, anti-sulfatide)
    • Autoimmune cerebellar degeneration
    • Gait Ataxia with Late age Onset Polyneuropathy (GALOP)
    • Stiff Person Syndrome
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Myasthenia Gravis
    • Lambert-Eaton myasthenic syndrome
    • Human T-cell lymphotropic virus (HTLV)-1-associated myelopathy (HAM) / tropical spastic paraparesis (TSP)
    • Opsoclonus/myoclonus (anti-Ri)
    • Neuromyelitis optica
    • Multiple sclerosis
    • Other central or peripheral nervous system autoimmune diseases as approved by study neurologists and the Fred Hutchinson Cancer Research Center (FHCRC) faculty at Patient Care Conference (PCC)
  • Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined
  • Patients age =\< 70 years
  • Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic resonance imaging of the brain or clinical progression)
  • Patients must have failed at least 2 lines of standard therapy as outlined for the specific diseases
  • DONOR: Sibling of any patient enrolled on this protocol proven by ABO typing, human leukocyte antigen (HLA) typing and variable number tandem repeat (VNTR) analysis to be syngeneic with the patient (e.g. identical twin)
  • DONOR: Willing to undergo multiple apheresis procedures (except donors \< 12 years who will undergo bone marrow harvests)

Exclusion criteria

Exclusion Criteria:

  • Age >= 71 years
  • Pregnancy or expressed plans to become pregnant within 1 year of the procedure
  • Patients who are serologically positive for (HIV)
  • Patients with pulmonary, cardiac, hepatic or renal impairment that would limit their ability to receive cytoreductive therapy and compromise their survival; this should include patients with any of the following:

    • Severe pulmonary dysfunction associated with a carbon monoxide diffusing capacity (DLCO) (corrected for ) \< 60%, or requires supplemental oxygen; patients who are unable to perform pulmonary function test (because of underlying disease) will be excluded if the oxygen saturation is \< 92% on room air
    • Uncontrolled malignant arrhythmias, or clinical evidence of congestive heart failure (New York class III-IV) or \< 50%
    • Renal disease with estimated (GFR) by or iothalamate clearance \< 50 ml/min/1.73 m\^2 body surface area
    • Serum glutamate pyruvate transaminase ()/aspartate aminotransferase (AST) > 3 times normal or direct greater than 2.5 mg/dL on two repeated tests
  • Active uncontrolled infection
  • Demonstrated lack of compliance with prior medical care
  • Patients whose is limited by illness other than their neurological condition
  • Patients with evidence of myelodysplasia
  • Active (excluding localized squamous cell or basal cell carcinoma of the skin)
  • DONOR: Inadequate documentation that donor and recipient are syngeneic
  • DONOR: Donors who do not fulfill criteria as apheresis donors as established by institutional guidelines
  • DONOR: Concordant for neurological disease(s) as determined by neurological evaluation
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Treatment (immunosuppressive therapy followed by transplant)

    Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.

    Biological: Anti-Thymocyte Globulin · Procedure: Autologous Hematopoietic Stem Cell Transplantation · Drug: Carmustine · Drug: Cytarabine · Drug: Etoposide · Other: Laboratory Biomarker Analysis · Drug: Melphalan · Procedure: Peripheral Blood Stem Cell Transplantation · Drug: Prednisone · Procedure: Syngeneic Bone Marrow Transplantation

Interventions

  • BiologicalAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin

  • ProcedureAutologous Hematopoietic Stem Cell Transplantation

    Undergo autologous or syngeneic stem cell transplantation

    Also known as: Autologous Stem Cell Transplantation

  • Given IV

    Also known as: BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, 154-93-8

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, 147-94-4

  • Given IV

    Also known as: Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, 33419-42-0

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given IV

    Also known as: Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, 148-82-3

  • ProcedurePeripheral Blood Stem Cell Transplantation

    Undergo autologous or syngeneic stem cell transplantation

    Also known as: PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, 53-03-2

  • ProcedureSyngeneic Bone Marrow Transplantation

    Undergo syngeneic bone marrow transplantation

07

What researchers measure

Primary outcomes

  1. Incidence of grades 4-5 regimen-related toxicity

    Assessed by the Regimen Related Toxicity Scale. Using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The development of a grade 4 to 5 toxicity of any of the included major organ systems within the first 365 days after transplant will be defined as regimen-related toxicity.

    Time frame: Up to 1 year post-transplant

Secondary outcomes

  1. Transplant-related mortality

    Defined as death within the first 100 days of transplant due to transplant-related complications.

    Time frame: Within 100 days post-transplant

  2. Disease responses

    Assessed by clinical, laboratory and radiologic evaluation

    Time frame: Up to 5 years

  3. Engraftment kinetics

    Monitored for engraftment kinetics of granulocytes, platelets and red cells post-transplant.

    Time frame: Over first 60 days post-transplant

  4. Number of subjects achieving greater than or equal to 4.0 x 10^6 CD34+ cells/kg, after up to two peripheral blood stem cell mobilizations

    Efficacy of peripheral blood stem cell mobilization as evaluated by total number of harvested CD34+cells/kg, for autologous transplant.

    Time frame: Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)

  5. Number of subjects with an exacerbation of autoimmune disease symptoms secondary to G-CSF (filgrastim) during peripheral blood stem cell mobilization

    Subjects are evaluated by standardized clinical neurologic tests specific to autoimmune disease type.

    Time frame: Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)

08

Study locations

3 sites
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Dec 2025 and a completion of Jan 2030. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2008
First posted
Jul 16, 2008
Start
Jun 2008
Primary completionActual
Dec 30, 2025
CompletionEst.
Jan 31, 2030
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00716066
Responsible party
Sponsor
First posted
Jul 16, 2008
Start date
Jun 2008
Primary completion
Dec 30, 2025
Completion
Jan 31, 2030 (estimated)
Last update
Feb 27, 2026

Study contacts

Leona Holmberg
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Carmustine · Cytarabine · Etoposide · Melphalan

Start the discussion